Janus Kinase Family - JAK 1, 2, 3 & TYK2 and How They Will Impact Your Treatment of Psoriasis: Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

This presentation was recorded at the 2020 Fall Clinical Dermatology Conference. This activity is supported by an educational grant from Bristol Myers Squibb.

Mark Lebwohl, MD

Faculty

Dean for Clinical Therapeutics
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Understand the immune/inflammatory cascade and their role in pathophysiology of psoriasis and other dermatologic conditions
Become familiar with the current and emerging JAK inhibitor therapies
Discern the clinical relevance of and indications for the JAK inhibitors and TYK2 inhibitors for psoriasis
Understand the safety and efficacy profile of the various JAK inhibitors
Recognize the clinical advantages and limitations of different JAKs and TYK2-inhibitor therapy for patients with psoriasis and other related immune-related diseases

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients with immune related diseases in dermatology.

Faculty Disclosures

Mark Lebwohl, MD

Consultant: Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, Boehringer-Ingelheim, Bristol-Myers Squibb, Cora therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO, meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/ Dr. Reddy’s abs, Theravance, Verrica

Grant/Research Support: Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, Kadmon Corp., LEO, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm UCB, ViDac

This CME activity is supported by an educational grant from Bristol-Myers Squibb.

[fc+322]